TONGRENTANGCM (03613.HK) has entered into a technical service contract with TONG REN TANG.

On December 20, Glonghui reported that TONGRENTANGCM (03613.HK) announced that on December 20, 2024, the company entered into a technical service contract with TONG REN TANG. According to this, the company entrusted TONG REN TANG to conduct process and technical research on important Traditional Chinese Medicine raw materials. The company should pay a total of 5 million HKD to TONG REN TANG in installments for the technical services. These raw materials are an important part of the group's production of Traditional Chinese Medicine and products, and their quality plays a crucial role in the group's production process. Considering TONG REN TANG's capabilities and expertise in Traditional Chinese Medicine manufacturing, the Directors believe that the technical service contract and the transactions involved will be beneficial.

Gelonghui FinanceDec 20 18:44

Beijing Tong Ren Tang Extends Key Procurement Deal

TipRanksDec 20 18:37

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.

HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.

Zhitong FinanceDec 13 07:20

Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities

BreakingsDec 12 07:38

Behind winning two major awards, tong ren tang (01666.HK) focuses on investors and anchors on high-quality development.

This choice will also become a "ballast" for its future performance growth and value creation, enabling ckh holdings to develop in a long-term and stable manner.

Gelonghui FinanceDec 6 15:22